Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Nuvig Raises $161M for Phase 2 Immunomodulator Development Progression
Details : The proceeds from the financing will support clinical studies for NVG-2089. The company is progressing NVG-2089 to mid-stage clinical development in chronic inflammatory demyelinating polyneuropathy.
Product Name : NVG-2089
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
December 05, 2024
Lead Product(s) : NVG-2089
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089
Details : NVG-2089 is a recombinant immunomodulator targeting type II Fc receptors, developed for inflammatory myopathies and severe autoimmune skin diseases.
Product Name : NVG-2089
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : NVG-2089
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Organovo Holdings
Deal Size : $47.0 million
Deal Type : Series A Financing
Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases
Details : Nuvig is building a pipeline of differentiated protein therapeutics that specifically target affected tissues in a disease-specific manner and can be used in the context of varied but well-defined disease mechanisms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
November 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Organovo Holdings
Deal Size : $47.0 million
Deal Type : Series A Financing
Reset All
